Search

Quinazolinone and thiouracil derivatives are key scaffolds in anticancer development. This study used a molecular hybridization approach to synthesize new quinazolinone‐thiouracil derivatives and evaluated their anticancer activity against three human cancer cell lines, namely breast, lung, and glioblastoma, using SRB assay. Structural elucidation was performed using IR spectroscopy, 1H‐NMR, 13C‐NMR, mass spectrometry, and elemental analysis. Most compounds show moderate to significant cytotoxic effects, with compound 5d displaying the highest potency (IC50 values of 5.28, 4.02, and 2.88 µM, respectively). Compound 5d also demonstrated comparable potency to positive controls cisplatin and temozolomide in lung and glioblastoma cancer cell lines and was nearly as effective as mitochondrial division inhibitor‐1 (mdivi‐1). Furthermore, molecular docking analyses revealed strong binding interactions of the synthesized compounds with dynamin‐related protein‐1 (drp1). Protein–ligand stability studies and all‐atom simulation confirmed the stable binding of compound 5d with drp1. In conclusion, this study identified compound 5d as a potent drp1 inhibitor and promising anticancer drug candidate, deserving further investigation. [ABSTRACT FROM AUTHOR]

Objective: Novel 2,3-disubstituted 4-oxoquinazoline-3(4H) derivatives containing oxadiazole, thiazolidinone ring, the 4-oxoquinazoline-3(4H) Schiff bases, and carbothioamide structure were synthesized. All the synthesized compounds' urease and acetylcholinesterase enzyme inhibitions were evaluated in vitro. Methods: The chemical structures of the synthesized compounds were confirmed using IR, 1H, and 13C NMR spectral methods. For all newly synthesized compounds, the urease enzyme inhibition activity was measured using the Weatherburn method, and the acetylcholinesterase enzyme inhibition activity was measured using the Ellman method with slight modifications. Results and Discussion: All newly synthesized compounds showed urease enzyme inhibition in the range of IC50 = 11.00 ± 0.10 to 17.45 ± 0.25 µg/mL compared to standard thiourea (IC50 = 15.75 ± 0.25 µg/mL). Among the synthesized compounds, quinazolinone containing oxadiazole ring (IVa–IVd) and thiosemicarbazide structure (IXa–IXd) showed the most inhibition. Most of the synthesized compounds exhibited good inhibitory activities against acetylcholinesterase compared to the standard inhibitor Galantamine (IC50 = 20.45 ± 0.25 µg/mL), in the range of 16.44 ± 0.26 to 30.50 ± 0.50 µg/mL. Furthermore, the molecular docking study was performed to determine the interaction modes of newly synthesized compounds at the active site of the target enzymes. ADMET properties were calculated to evaluate the drug-likeness of all compounds. Conclusions: In this study, a new series of quinazolinone derivative compounds with potentially active antiurease and antiacetylcholinesterase inhibitions were synthesized, consistent with in silico studies. [ABSTRACT FROM AUTHOR]

A convenient and concise base-promoted synthesis of 3,4-dihydro-2(1H)-quinazolinones and multi-membered cyclic ureas has been developed. In the presence of tBuOK, a variety of 3,4-dihydro-2(1H)-quinazolinones as well as the N-arylated five-, six- and nine-membered cyclic ureas were readily synthesized under mild conditions. This method offers an alternative synthesis toolkit towards cyclic ureas. [ABSTRACT FROM AUTHOR]

Introduction: The combination of BRAF and tyrosine kinase (TK) inhibitors has been demonstrated to be highly effective in inhibiting tumor development and is an approach for overcoming resistance in clinical trials. Accordingly, a novel series of 1,2,4-oxadiazole/quinazoline-4-one hybrids was developed as antiproliferative multitargeted inhibitors. Methods: The structures of the newly synthesized compounds 9a-o were validated using IR, NMR, MS, and elemental techniques. 9a-o were tested as antiproliferative agents. Results and Discussion: The results showed that the majority of the tested compounds showed significant antiproliferative action with 9b, 9c, 9h, 9k, and 9l being the most potent. Compounds 9b, 9c, 9h, 9k, and 9l were tested as EGFR and BRAF[sup V600E] inhibitors. These in vitro tests revealed that compounds 9b, 9c, and 9h are strong antiproliferative agents that may act as dual EGFR/BRAF[sup V600E] inhibitors. 9b, 9c, and 9h were further investigated for their inhibitory effect on mutant EGFR (EGFR[sup T790M]), and the results showed that the tested compounds had considerable inhibitory action. Cell cycle study and apoptosis detection demonstrated that compound 9b exhibits cell cycle arrest at the G2/M transition. Molecular docking simulations reveal the binding mechanism of the most active antiproliferative agents. [ABSTRACT FROM AUTHOR]

To develop aryloxyphenoxypropionate herbicides with novel structure and improved activity, a total of twenty-eight novel quinazolinone–phenoxypropionate derivatives containing a diester moiety were designed and synthesized. The herbicidal bioassay results in the greenhouse showed that QPEP-I-4 exhibited excellent herbicidal activity against E. crusgalli, D. sanguinalis, S. alterniflora, E. indica, and P. alopecuroides with inhibition rates >80% at a dosage of 150 g ha−1 and displayed higher crop safety to G. hirsutum, G. max, and A. hypogaea than the commercial herbicide quizalofop-p-ethyl. Studying the herbicidal mechanism by phenotypic observation, membrane permeability evaluation, and transcriptomic analysis revealed that a growth inhibition of plants by QPPE-I-4 was the result from damage of the plants' biomembrane. The evaluation of ACCase activity in vivo indicated that QPPE-I-4 could inhibit ACCase and may be a new type of ACCase inhibitor. The present work indicated that QPPE-I-4 could represent a lead compound for further developing novel AOPP herbicides. [ABSTRACT FROM AUTHOR]

New triheteroyclic compounds containing quinazolinone, thiophene, andthiadiazole /thiazolidinone structureswere synthesized and characterized by FT-IR, 1H–NMR, and13C–NMRspectral data. The new compounds' inhibitory activities on urease and acetylcholinesterase were assessed. All triheterocyclic compounds with thiadiazole ring have urease and acetylcholinesteraseinhibitory activities.Especially compound 5a; 3-[(5-(phenylamino)-1,3,4-thiadiazol-2-yl]methyl-2-(thiophen-3-ylmethyl)quinazolin-4(3H)-onehas the best urease inhibition result with 13.30 ± 0.15 µg/mL IC50 value, and it also has the best acetylcholinesterase inhibition with 20.30 ± 0.15 µg/mL IC50 value. [ABSTRACT FROM AUTHOR]

Heterostructures of CuFe2O4@NH2-MIL-88B (Fe) were effectively synthesized and utilized as an effective catalyst under visible light and oxidation conditions for the synthesis of quinazolinones. At room temperature, good to excellent yields of the desired products were obtained. In addition, the composite heterostructures that were created showed a higher level of photocatalytic activity when exposed to visible light compared to both CuFe2O4 and NH2-MIL-88B (Fe) individually. In comparison with CuFe2O4 and MIL-88B (Fe), the absorption peak of CuFe2O4/MIL has increased. Increasing visible light absorption could lead to an increase in electron–hole pair formation, which would improve photocatalytic activity. Furthermore, the incorporation of CuFe2O4 to the NH2-MIL 88B (Fe) surface results in a significant reduction in photoluminescence emission intensity. Moreover, from the perspective of sustainable chemistry, CuFe2O4@NH2-MIL-88B (Fe) demonstrated good recyclability, being recycled six times with little to no loss in catalytic efficacy. [ABSTRACT FROM AUTHOR]

Novel 1,2,3‐triazole acetamide linked quinazolinone derivatives were synthesized via click reaction, by reacting of 3‐methyl‐2‐(prop‐2‐yn‐1‐ylthio)quinazolin‐4(3H)‐one with various aryl azides as prominent fungal pathogen Candida albicans interactions. The prepared triazole compounds were characterized using mass spectrometry, 1H NMR, 13C NMR, and IR spectroscopic techniques. Compounds were screened for their in vitro antibacterial and antifungal activity against a variety of microorganisms namely, Bacillus subtilis, Enterococcus faecalis, Klebsiella pneumonia, Escherichia coli, Aspergillus fumigatus, Candida albicans, and Aspergillus clavatus. Quinazolinone linked p‐hydroxyphenyl, o, p‐dihydroxyphenyl and o‐dimethylamino phenyl triazoles showed a remarkable antibacterial activity against E. faecalis with MIC values of 3.20±0.01, 4.01±0.04, and 4.10±0.01 μg mL−1, and screened compounds p‐nitrophenyl substituted triazole, and p‐methylphenyl substituted triazole displayed a significant antifungal activity against C. albicans with MICs of 3.16±0.01, 4.06±0.03 μg mL−1, compared to itraconazole (MIC=3.32±0.02 μg mL−1). For further exploration of the anti‐fungal mechanism of action, molecular docking was carried out for these compounds in C. albicans active site as one of the important antifungal inhibitors (PDB: 1A19). Furthermore, the ADMET profile was evaluated for all the final triazole compounds in contrast to reference drugs moxifloxacin and itraconazole. In conclusion, we discovered a novel quinazolinone linked 1,2,3‐triazoles with promising antimicrobial activity and a favorable pharmacokinetic profile. [ABSTRACT FROM AUTHOR]

Objective: This research aims to synthesize and characterize a new series of bioactive quinazoline derivatives, including Schiff bases, biquinazolinone, and benzothiazine, and to evaluate their bioactivity as antioxidants through both in silico and in vitro investigations. Methods: The new derivatives were synthesized with high yields by reacting Schiff base derivatives of quinazoline with 2-aminobenzoic acid and 2-mercaptobenzoic acid. The characterization of the prepared derivatives was carried out using FTIR, 1H NMR, and 13C NMR techniques. In silico investigations included assessing pharmacokinetic and pharmacodynamic properties through the SwissADME online server and conducting molecular docking studies with the tyrosinase enzyme. In vitro assessments involved evaluating antioxidant activity using the total antioxidant capacity method and the DPPH scavenging activity method. Results and Discussion: In silico analysis revealed favorable pharmacokinetic and pharmacodynamic properties for all compounds. Compounds (III) and (IV) exhibited acceptable pharmacological characteristics. Molecular docking studies showed good docking scores for all compounds with the tyrosinase enzyme. In vitro assessments demonstrated noteworthy to excellent antioxidant activity for all compounds, with compounds (III) and (IV) exhibiting very strong activity compared to the standard reference, ascorbic acid. Conclusions: The synthesized quinazoline derivatives exhibit promising bioactivity as antioxidants, supported by both computational and experimental assessments. These findings suggest their potential for further exploration in the development of antioxidant agents, with particular emphasis on the notable performance of compounds (III) and (IV). [ABSTRACT FROM AUTHOR]

Copper‐catalyzed and visible‐light catalytic difluoroalkylation reactions of N‐cyanamide alkenes have been developed. Various α‐bromodifluoromethyl substituted esters, amides and heterocycles were employed as the CF2 source. Both protocols are characterized by medium to high yields, good functional group compatibility, and applicable to gram‐scale synthesis. Comparable studies of copper catalysis and photoredox catalysis demonstrate minimal differences between the two protocols. Preliminary mechanism suggest that both transformations involve tandem radical cyclization process. [ABSTRACT FROM AUTHOR]

Heterocyclic compound such as quinazoline derivatives shows wide range of medicinal application in the area such as anticonvulsant, antitumor, antifungal, antimalaria, anti-hyperlipidemic and anti-inflammatory etc. activity because of these it shows great interest to study. In the presence study, we have synthesized triazole based quinazolinones by condensation reaction between α-methyl ketone and aromatic aldehydes under ethanol as the solvent to produced chalcones derivatives. This chalcone derivative have α,β-unsaturated part which is enhanced the reactivity of compound. Chalcone further reacted with 2-aminotriazole under alkali media in the presence of ethanol as the solvent to produced quinazolinone. This prepared compound has further possibility to modified at N atom upon reaction with halogen containing compound. Prepared quinazolinone were further treated with cyanuric chloride to increase heterocyclic part in the compound. Characterization of all synthesized product were done using spectroscopic techniques. All prepared compounds were screen for their biological evaluation against gram+ve and gram-ve bacteria. [ABSTRACT FROM AUTHOR]

We described a base‐promoted O‐arylation of N3‐hydroxyl quinazolinones with diaryliodonium salts and sequential BF3 ⋅ OEt2 and visible light‐controlled [3,3]‐ or [1,3]‐rearrangements of quinazolinone N−O aryl moieties to prepare a variety of 2‐(quinazolin‐4‐yloxy)phenols and atropisomeric 3‐(2‐hydroxyphenyl)quinazolin‐4‐ones in 44%‐75% yields and 28%‐70% yields, respectively. Mechanistic studies showed that HBF4 generated in situ from BF3 ⋅ Et2O and water served as the catalyst in this process and aryloxyquinazolinium salts are vital intermediates promoting the [3,3]‐ or [1,3]‐rearrangements. The N−O aryl moieties of aryloxyquinazolinium salts were found to undergo solely [3,3]‐rearrangement with heating whereas [1,3]‐rearrangement occurred via a radical process under irradiation of visible light. This method highlights the formation of aryloxyquinazolinium salts based on the use of BF3 ⋅ OEt2 and visible light to prompt [1,3]‐rearrangement generating atropisomeric quinazolinones. [ABSTRACT FROM AUTHOR]

Some novel 3-aminoquinazolin-4(3H)-one derivatives were synthesized by the reaction of 2-aminobenzhydrazide and corresponding iminoester hydrochlorides and then reacted with coumarin-3-carbonyl chloride to obtain novel coumarin–quinazolinone hybrids. The synthesized hybrid compounds were screened for their anticancer activity against various human cancer and normal cell lines. N-{2-[(4-Bromo- and N-{2-[(3-bromo-phenyl)methyl]-4-oxoquinazolin-3(4H)-yl}-2-oxo-2H-1-benzopyran-3-carboxamides exhibited the highest cytotoxic effect on the PC-3 prostate cancer cell line: IC50 35.3 ± 0.6 and 36.8 ± 0.8 µg/L, respectively. N-{2-[(4-Fluoro-, N-{2-[(4-bromo-, and N-{2-[(3,4-dichloro-phenyl)methyl]-4-oxoquinazolin-3(4H)-yl}-2-oxo-2H-1-benzopyran-3-carboxamides showed the highest activity against the MCF-7 breast cancer cell line: IC50 48.5 ± 0.4, 44.8 ± 0.4 and 46.1 ± 0.5 µg/L, respectively. [ABSTRACT FROM AUTHOR]

A new quinazolinone alkaloid named peniquinazolinone A (1), as well as eleven known compounds, 2-(2-hydroxy-3-phenylpropionamido)-N-methylbenzamide (2), viridicatin (3), viridicatol (4), (±)-cyclopeptin (5a/5b), dehydrocyclopeptin (6), cyclopenin (7), cyclopenol (8), methyl-indole-3-carboxylate (9), 2,5-dihydroxyphenyl acetate (10), methyl m-hydroxyphenylacetate (11), and conidiogenone B (12), were isolated from the endophytic Penicillium sp. HJT-A-6. The chemical structures of all the compounds were elucidated by comprehensive spectroscopic analysis, including 1D and 2D NMR and HRESIMS. The absolute configuration at C-13 of peniquinazolinone A (1) was established by applying the modified Mosher's method. Compounds 2, 3, and 7 exhibited an optimal promoting effect on the seed germination of Rhodiola tibetica at a concentration of 0.01 mg/mL, while the optimal concentration for compounds 4 and 9 to promote Rhodiola tibetica seed germination was 0.001 mg/mL. Compound 12 showed optimal seed-germination-promoting activity at a concentration of 0.1 mg/mL. Compared with the positive drug 6-benzyladenine (6-BA), compounds 2, 3, 4, 7, 9, and 12 could extend the seed germination period of Rhodiola tibetica up to the 11th day. [ABSTRACT FROM AUTHOR]

Herein, we reported a selective, mild method for the visible‐light‐photocatalyzed trifluoromethylation and cyclization of unactivated tethered alkenes to provide tri‐ and tetracyclic quinazolinones. Trifluoroacetic acid and anhydride are inexpensive and readily available reagents for the process that proceeds without the addition of a strong oxidant. The wide substrate scope and the formation of 5‐ and 6‐membered rings are demonstrated in 44–82 % yields. Control experiments provide the basis for a proposed mechanism involving photocatalyzed SET from fac‐Ir(ppy)3 to TFAA and trifluoromethyl radical‐mediated regioselective cyclization. The practicality of the protocol was illustrated by a gram‐scale synthesis in 76 % yield. [ABSTRACT FROM AUTHOR]

IntroductionThe combination of BRAF and tyrosine kinase (TK) inhibitors has been demonstrated to be highly effective in inhibiting tumor development and is an approach for overcoming resistance in clinical trials. Accordingly, a novel series of 1,2,4-oxadiazole/quinazoline-4-one hybrids was developed as antiproliferative multitargeted inhibitors.MethodsThe structures of the newly synthesized compounds 9a-o were validated using IR, NMR, MS, and elemental techniques. 9a–o were tested as antiproliferative agents.Results and DiscussionThe results showed that the majority of the tested compounds showed significant antiproliferative action with 9b, 9c, 9h, 9k, and 9l being the most potent. Compounds 9b, 9c, 9h, 9k, and 9l were tested as EGFR and BRAFV600E inhibitors. These in vitro tests revealed that compounds 9b, 9c, and 9h are strong antiproliferative agents that may act as dual EGFR/BRAFV600E inhibitors. 9b, 9c, and 9h were further investigated for their inhibitory effect on mutant EGFR (EGFRT790M), and the results showed that the tested compounds had considerable inhibitory action. Cell cycle study and apoptosis detection demonstrated that compound 9b exhibits cell cycle arrest at the G2/M transition. Molecular docking simulations reveal the binding mechanism of the most active antiproliferative agents.

The current study outlines a straightforward and efficient method for creating new quinazolinone disperse dyes based on pyrazolone moieties, starting with quinazolinone and a variety of substituted pyrazolone as couplers. The synthesized dyes were characterized using a variety of spectroscopic and analytical methods. The synthesized dyes' ultraviolet–visible spectra showed bands brought on by several molecular transitions. We investigated in detail the multifunctional characteristics such color representation, dyeing duration, concentration, pH, buildup, and fastness properties of the dyed samples. Fastness properties and colorimetric data showed satisfactory results, demonstrating the effectiveness of these dyes in dyeing polyester fabrics. A pH of 5 and a dyeing temperature of 130 °C were the ideal conditions for dyeing polyester fabrics. Additionally, an ultraviolet protection factor test was performed on the dyed fabrics, and the results showed that these dyes provide the best UV protection. These dyes are suitable for industrial dyeing applications since they are easy to manufacture and scale up. Additionally, in-vitro testing was done to determine the dyes' antibacterial effectiveness against various bacteria and fungi. The antibacterial activity of the dyes was moderate to very good against both Gram-positive and Gram-negative bacteria, as well as fungi. [ABSTRACT FROM AUTHOR]

A facile intramolecular [1,5] hydride transfer reaction in a Dihydroquinazolin‐4(1H)‐one moiety synthesized from anthranilamide, glutaraldehyde, and aromatic amines is described in isopropanol medium in the presence of catalytic HCl. Based on that, we have designed a simple, efficient strategy for conjugating quinazolinone, a pharmaceutically active moiety, with an aromatic amine through an aliphatic spacer. The use of isopropanol as a reaction medium at RT and isolation of the product without rigorous column purification make the process a step ahead towards sustainability. One of the synthesized compounds was evaluated as a small molecule DNA binder. Detailed binding properties were investigated by the multispectroscopy methods. [ABSTRACT FROM AUTHOR]

6,7-Bis-(2-methoxyethoxy)-4(3 H)-quinazolinone (BMEQ) was selected from quinazolinones for its strong tyrosinase inhibitory activity (IC 50 = 160 ± 6 μM). It suppressed tyrosinase activity in a competitive way and quenched the fluorescence of the enzyme through a static mechanism. The binding of BMEQ to tyrosinase increased the hydrophobicity of the latter and facilitated non-radiative energy transfer between them. The formation of BMEQ–tyrosinase complex was driven by hydrogen bonds and hydrophobic interactions, and it loosened the basic framework structure of tyrosinase, affecting the conformation of the enzyme, and leading to a decrease in tyrosinase activity. In addition, the BMEQ postponed the oxidation of phenolics and flavonoids by inhibiting polyphenol oxidase (PPO) and peroxidase (POD), which resulted in the inhibition of the browning of fresh-cut apples. This study identified a novel tyrosinase inhibitor BMEQ and verified its potential application for improving the preservation of postharvest fruits. [Display omitted] [ABSTRACT FROM AUTHOR]

This paper presents a amidinyl transfer reagent for the synthesis of nitrogen‐containing compounds, wherein N,N‐dimethylformamide is used as the C1 source to react with hexamethyldisilazane, generating the N,N‐dimethylformimidamide intermediate. This intermediate is then reacted with amines to induce amidinyl transfer. This protocol can be applied for the synthesis of N‐formamide, benzimidazole and quinazolinone, for which amine derivatives used as substrates under optimized conditions. The advantages of this method are its operational simplicity, high efficiency, structural diversity in products with favorable yields, and applicability in gram‐scale operations. [ABSTRACT FROM AUTHOR]

An efficient palladium‐catalyzed annulation of 3‐arylquinazolinones with mono and double alkyne insertion was developed for the synthesis of fused quinazolinone derivatives in 43–80 % yields. A notable effect was observed in product yield, when bases/additives were modulated. The reaction mechanism is believed to proceed through C−X cleavage/alkyne insertion/1,4‐Pd migration and C−H annulation in a one‐pot manner. [ABSTRACT FROM AUTHOR]

Cancer is a broad classification of diseases that can affect any organ or body tissue due to aberrant cellular proliferation for unknown reasons. Many present chemotherapeutic drugs are highly toxic and have little selectivity. Additionally, they lead to the development of medication resistance. Therefore, developing tailored chemotherapeutic drugs with minimal side effects and good selectivity is crucial for cancer treatment. 2-(1H)-Quinazolinone is one of the vital scaffold and anticancer activity is one of the prominent biological activities of this class. Here we report the novel set of amide-enriched 2-(1H)-quinazolinone derivatives (7a-j) and their apoptotic activity with the help of MTT assay method against four human cancer cell lines: PC3 (prostate cancer), DU-145 (prostate cancer), A549 (lung cancer), and MCF7 (breast cancer). When compared to etoposide, every synthetic test compound (7a-j) exhibited moderate to excellent activity. The IC50 values of the new amide derivatives (7a-j) varied from 0.07 ± 0.0061 μM to 10.8 ± 0.69 μM. While the positive control, etoposide, exhibited 1.97 ± 0.45 μM to 3.08 ± 0.135 μM range. Among the novel amide derivatives (7a-j), in particular, 7i and 7j showed strong apoptotic activity against MCF7; 7h showed against PC3, and 7g showed against DU-145. Molecular docking studies of test compounds (7a-j) with the EGFR tyrosine kinase domain (PDB ID: 1M17) protein provided the significant docking scores for each test compound (7a-j) (−9.00 to −9.67 kcal/mol). Additionally, DFT investigations and MD simulations validated the predictions of molecular docking. According to the findings of the ADME analysis, oral absorption by humans is anticipated to be higher than 85 % for all test compounds.

To develop aryloxyphenoxypropionate herbicides with novel structure and improved activity, a total of twenty-eight novel quinazolinone–phenoxypropionate derivatives containing a diester moiety were designed and synthesized. The herbicidal bioassay results in the greenhouse showed that QPEP-I-4 exhibited excellent herbicidal activity against E. crusgalli, D. sanguinalis, S. alterniflora, E. indica, and P. alopecuroides with inhibition rates >80% at a dosage of 150 g ha−1 and displayed higher crop safety to G. hirsutum, G. max, and A. hypogaea than the commercial herbicide quizalofop-p-ethyl. Studying the herbicidal mechanism by phenotypic observation, membrane permeability evaluation, and transcriptomic analysis revealed that a growth inhibition of plants by QPPE-I-4 was the result from damage of the plants’ biomembrane. The evaluation of ACCase activity in vivo indicated that QPPE-I-4 could inhibit ACCase and may be a new type of ACCase inhibitor. The present work indicated that QPPE-I-4 could represent a lead compound for further developing novel AOPP herbicides.

Benzoxazine and quinazoline are nitrogen-containing heterocyclic scaffolds found in various biologically active compounds. Due to their diverse biological actions, these heterocyclic rings serve as crucial frameworks for designing medicinal compounds. This study aimed to synthesize and assess in vivo anti-inflammatory, analgesic, and low ulcerogenic potential of a few novel benz[d][1,3]-oxazine-4-one and quinazolinone derivatives. Benzoxazinones (3a-e) were synthesized by cyclizing the carboxylic group (-COOH) of five nonsteroidal anti-inflammatory drugs viz., aceclofenac, ibuprofen, diclofenac, mefenamic acid and ketoprofen (2a-e) with anthranilic acid (1) using dry phosphorus oxychloride (POCl3 ) in pyridine. The corresponding quinazolinone derivatives (5a-e) were obtained by reacting 3a-e with isonicotinic acid hydrazide (4). Both sets of compounds were evaluated for their anti-inflammatory, analgesic effects, and ulcerogenicity in animal models. Structural characterization was performed using spectral analysis. Among the benzoxazinone derivatives, compound 2-(2-((2,6-dichlorophenyl) amino) benzyl)-4H-benzo[d][1,3]oxazin-4-one (3d) exhibited significant anti-inflammatory activity (62.61% inhibition of rat paw edema) and analgesic activity (62.36% protection in acetic acid-induced writhings) with tolerable gastrointestinal toxicity (2.67 ulcerogenicity index) compared to quinazolinone derivatives. The results of antiinflammatory and analgesic activities of both the series are comparable with the respective, positive control. Compound 3d, a benzoxazinone-diclofenac hybrid, emerged as a lead molecule with potent anti-inflammatory, analgesic activities and moderate gastric toxicity showcasing the promising potential for further development. [ABSTRACT FROM AUTHOR]

New methods have been developed for the synthesis of the substituted quinolines and quinazolinones derivatives by utilizing N-(2-aminobenzoyl)benzotriazoles under mild reaction conditions. 3-Acyl-2-alkyl(aryl)-4-hydroxyquinolines were obtained in modarete yields by the reaction of N-(2-aminobenzoyl)benzotriazoles and diketones in the presence of tert-BuOK. 3-Acylamino-4(3H) quinazolinones were obtained in good yields via N-(2-aminobenzoyl)benzotriazoles, orthoester and hyrazides in one-pot. [ABSTRACT FROM AUTHOR]

In the current study, a series of 1,3,4-oxadiazole and 1,2,4-triazole derivatives linked to quinazolinone were designed and synthesized by using Phase Transfer Catalysis. The structures of the synthesized compounds were confirmed by their IR, 1H NMR, 13C NMR, and HR-ESI-MS spectroscopic data, and their in vitro antiproliferative activities against A549, Hela, MCF-7 as well as L929 were detected by using CCK-8 assay. The results demonstrated that most of the compounds showed better growth inhibitory effect than 5-FU on A549, Hela, and MCF-7 cell lines. Especially, 2-(5-((3-bromophenyl)thio)-1,3,4-oxadiazole-2-yl)quinazolin-4(3H)-one (8o), 4-amino-5-((4-nitrophenyl)thio)-4H-1,2,4-triazol-3-yl)quinazolin-4(3H)-one (9m) and 2-(4-amino-5-(o-tolylthio)-4H-1,2,4-triazol-3-yl)quinazolin-4(3H)-one (9b) showed good antiproliferative activity against A549 cells with IC50 value of 3.46, 2.96, and 3.44 μM, respectively. 2-(4-Amino-5-((3,5-difluorophenyl)thio)-4H-1,2,4-triazol-3-yl)quinazolin-4(3H)-one (9h) and 4-amino-5-((4-nitrophenyl)thio)-4H-1,2,4-triazol-3-yl)quinazolin-4(3H)-one (9m) had obvious inhibitory effects on Hela cells with IC50 values of 1.76 and 3.91 μM, respectively. 2-(4-Amino-5-((2-chlorophenyl)thio)-4H-1,2,4-triazol-3-yl)quinazolin-4(3H)-one (9i) showed high inhibitory activity against MCF-7 cells with IC50 value of 2.72 μM. Meanwhile, all compounds showed lower cytotoxicity to L929 cells than positive control drug 5-FU. In development, according to the above preliminary observation, these novel quinazolinones incorporating 1,3,4-oxadiazole and 1,2,4-triazole thioether moieties could become potential molecular templates for searching new antitumor agents. [ABSTRACT FROM AUTHOR]

Facile synthesis for true intermediate (E)‐ and Z‐2‐(((5‐bromo‐1‐(3‐chloropyridin‐2‐yl)‐1H‐pyrazol‐3‐yl)methylene)amino)‐5‐chloro‐3‐methylbenzoic acid precursors and 2‐(5‐bromo‐1‐(3‐chloropyridin‐2‐yl)‐1H‐pyrazol‐3‐yl)‐6‐chloro‐3,8‐dimethylquinazolin‐4(3H)‐one (QPP) as electron donor/electron acceptor to be working as efficient dye sensitizers. These new derivatives have a wide‐band gap photo‐catalysts semiconductor and are performing to spread to the visible‐light region to give more stability and efficiency towards biomedicine for different diseases. In the present work, the authors are suggesting the design and synthesis of new structures of QPP molecule with extended visible light absorptivity due to the extended π‐π/n‐π conjugations, to stimulate TiO2 nanoparticles in visible‐light region. The physicochemical characterizations confirmed the successful synthesis of QPP, TiO2, and QPP II/TiO2 samples with the proposed structures. Fixing of QPP on the TiO2 surface is refining the optical properties of TiO2 with enhancing the charge separation and generating the efficient antenna in the visible region. Furthermore, the QPP II/TiO2 sample achieved a threefold enhancement in the observed rate constant of the photo‐degradation of rhodamine B dye when compared to the bare TiO2. Finally, the effect of the scavengers was investigated by O2.− to be the most reactive species, and the mechanism of the enhancement was suggested for investigation of the proposed structures in various photo‐catalytic and biomedical applications. [ABSTRACT FROM AUTHOR]

Fluorescent organic nanoparticles (FONPs) have attracted much attention as a practicable and effective platform for detection applications. The present article describes the preparation of FONPs derived from the quinazolinone-based 2-(furan-2-yl)-2,3-dihydroquinazolin-4(1H)-one derivative FHDQ. Self-assembly of FHDQ in an aqueous medium resulted in the formation of FONPs through H-type aggregation and showed excellent fluorescence properties. The presence of other coexisting species solutions did not affect the selective fluorescence quenching observed with the addition of 4-nitrophenol (4-NP). The photophysical properties, i.e., UV-Vis absorbance, fluorescence emission, and lifetime measurements together with zeta particle sizer, support excited-state complex formation followed by a dynamic fluorescence quenching phenomenon in the emission of FDHQNPs. In the concentration range of 0 to 36 μg. mL - 1 , the detection limit of this turn-off sensor FDHQNPs against 4-NP was determined to be 0.01611 μM. Finally, the practicability of the FDHQNPs for the analysis of 4-NP in environmental samples was demonstrated. [ABSTRACT FROM AUTHOR]

Triple-negative breast cancer (TNBC) comprises 10 % to 20 % of breast cancer, however, it is more dangerous than other types of breast cancer, because it lacks druggable targets, such as the estrogen receptors (ER) and the progesterone receptor (PR), and has under expressed receptor tyrosine kinase, ErbB2. Present targeted therapies are not very effective and other choices include invasive procedures like surgery or less invasive ones like radiotherapy and chemotherapy. This study investigated the potential anticancer activity of some novel quinazolinone derivatives that were designed on the structural framework of two approved anticancer drugs, Ispinesib (KSP inhibitor) and Idelalisib (PI3Kδ inhibitor), to find out solutions for TNBC. All the designed derivatives (3a-l) were subjected to extra precision molecular docking and were synthesized and spectrally characterized. In vitro enzyme inhibition assay of compounds (3a, 3b, 3e, 3 g and 3 h) revealed their nanomolar inhibitory potential against the anticancer targets, KSP and PI3Kδ. Using MTT assay, the cytotoxic potential of compounds 3a, 3b and 3e were found highest against MDA-MB-231 cells with an IC50 of 14.51 µM, 16.27 µM, and 9.97 µM, respectively. Remarkably, these compounds were recorded safe against the oral epithelial normal cells with an IC50 values of 293.60 µM, 261.43 µM, and 222 µM, respectively. The anticancer potential of these compounds against MDA-MB-231 cells was revealed to be associated with their apoptotic activity. This was established by examination with the inverted microscope that revealed the appearance of various apoptotic features like cell shrinkage, apoptotic bodies, and membrane blebbing. Using flow cytometry, the Annexin V/PI-stained cancer cells showed an increase in early and late apoptotic cells. In addition, DNA fragmentation was revealed to occur after treatment with the tested compounds by gel electrophoresis. The relative gene expression of pro-apoptotic and anti-apoptotic genes revealed an overexpression of the P53 and BAX genes and a downregulation of the BCL-2 gene by real-time PCR. So, this work proved that compounds 3a, 3b, and 3e could be developed as anticancer candidates, via their P53-dependent apoptotic activity.

A new quinazolinone alkaloid named peniquinazolinone A (1), as well as eleven known compounds, 2-(2-hydroxy-3-phenylpropionamido)-N-methylbenzamide (2), viridicatin (3), viridicatol (4), (±)-cyclopeptin (5a/5b), dehydrocyclopeptin (6), cyclopenin (7), cyclopenol (8), methyl-indole-3-carboxylate (9), 2,5-dihydroxyphenyl acetate (10), methyl m-hydroxyphenylacetate (11), and conidiogenone B (12), were isolated from the endophytic Penicillium sp. HJT-A-6. The chemical structures of all the compounds were elucidated by comprehensive spectroscopic analysis, including 1D and 2D NMR and HRESIMS. The absolute configuration at C-13 of peniquinazolinone A (1) was established by applying the modified Mosher’s method. Compounds 2, 3, and 7 exhibited an optimal promoting effect on the seed germination of Rhodiola tibetica at a concentration of 0.01 mg/mL, while the optimal concentration for compounds 4 and 9 to promote Rhodiola tibetica seed germination was 0.001 mg/mL. Compound 12 showed optimal seed-germination-promoting activity at a concentration of 0.1 mg/mL. Compared with the positive drug 6-benzyladenine (6-BA), compounds 2, 3, 4, 7, 9, and 12 could extend the seed germination period of Rhodiola tibetica up to the 11th day.

A series of new quinazolinone derivatives (5a-l) were designed as 3CL protease inhibitors for SARS-CoV-2 infection. The designed derivatives were efficiently synthesized by S-alkylation/arylation of an intermediate, 6-fluoro-3-(4-fluorophenyl)-2-mercaptoquinazolin-4(3H)-one and their successful synthesis was established by analytical methods, viz. IR, 1H NMR, & 13C NMR spectroscopy. The in silico inhibitory potential against 3CLpro of SARS-CoV-2 were studied by means of docking and dynamics simulations, and compared with the co-crystallized ligand (VR4) of SARS-CoV-2 3CLpro. The compounds interacted strongly within the active catalytic dyad (Cys-His) site, thereby anticipated to obstruct the function of 3CLpro of SARS-CoV-2. Compounds 5b, 5c, 5i, 5j and 5l showed efficient binding with protease 3CLpro with XP Gscore of −7.4, −8.3, −7.8, −7.5 and −8.2 respectively. Furthermore, molecular dynamic simulation study of these compounds (5b, 5c, 5i, 5j and 5 l) showed stable interaction over 50 ns production run. Swiss ADME and pkCSM web tools showed favorable physicochemical and pharmacokinetic properties and fulfilled the criteria for drug-likeness of these selected studied compounds. The toxicity determination of these selected compounds predicted that some compounds were hepatotoxic, but were not AMES toxic. Compounds 5b, 5c, 5i, 5j and 5 l revealed their inhibitory potential against the SARS-CoV-2 3CLpro, and their IC50 values were attained at 1.58, 1.25, 1.97, 0.44 and 2.56 µM, respectively. In addition, these compounds were found to have devoid of any significant cytotoxicity even at a higher concentration of 20 µM against VeroE6 cells. These quinazolinone derivatives showed potent binding and inhibitory potential against SARS-CoV-2 3CLpro and may emerge as compounds that might act as prospective inhibitors.

[Display omitted] • ortho -directed C H benzoxylation of simple 2-phenyl quinazolinones with palladium assistance has been developed. • Ceric ammonium nitrate, a potent single-electron oxidizing agent, was employed as an oxidant. • Simple and readily accessible aromatic carboxylic acids were utilized as a source of benzoxylate. • A one-pot method exhibiting great regioselectivity with good to modest yields. A simple protocol for a regioselective cross dehydrogenative reaction of 2-aryl-quinazolinones with different phenyl carboxylic acids was developed using a palladium catalyst facilitated by C H activation. Simple and readily accessible aromatic carboxylic acids were utilized as a source of benzoxylate. A one-pot method proceeded with great regioselectivity and offered mono benzoxylation product with moderate to excellent yield. [ABSTRACT FROM AUTHOR]

• 8-Methyl-2-phenyl quinazolinone Schiff's base series has been synthesized. • Efficacy of 7b and 7 h against MDA-MB-435 and NCI-H522 cell lines, respectively. • 7 g was effective against breast cancer (HS-578T) and CNS cancer (SNB-19) cell lines. • 7d (4-Br) and 7j (4-Cl) potent against selected bacterial and fungal microorganisms. • 7d and 7j show target affinities with −8 to −12.5 kcal/mol binding energies. A series of new compounds based on 8-methyl-2-phenyl quinazolinone Schiff's base were synthesized from 3-amino quinazolinone intermediates. These compounds were evaluated for their potential as anticancer and antimicrobial agents through docking analysis. Anticancer evaluation was done against sixty different cancer cell lines. Compounds 7b and 7 h showed strong efficacy against Melanoma (MDA-MB-435 Cell lines) and Non-Small Cell Lung Cancer (NCI-H522), respectively. Compound 7 g was found to be predominantly effective against both breast cancer (HS-578T) and central nervous system cancer (SNB-19). The antimicrobial activity results showed that the newly synthesized compounds 7d and 7j, which contain halogen, exhibited potential inhibiting action against selected bacterial and fungal microorganisms. The SAR study revealed that compounds with EDGs like hydroxyl and meta -substituted chloro group were found to be more potent in anticancer studies; while compounds with EWGs substituted in the para position (7d and 7j) demonstrated higher antimicrobial activity. Moreover, Antimicrobial docking analysis indicated that compounds 7d and 7j have a high affinity towards molecular targets found in both bacteria and fungi, with negative binding energies ranging from -8 to -12.5 kcal/mol. We endorse further evaluation of these compounds in combination with standard antibiotics to potentially increase their synergistic effect. [Display omitted] [ABSTRACT FROM AUTHOR]

A method for synthesizing polycyclic quinazolinone derivatives with ketoalkyl substitutions has been developed through strong acid-catalyzed radical tandem alkylation/cyclization of unactivated alkenes with readily available ketones under microwave irradiation. The transformation offers several advantages, including wide functional group compatibility, operational simplicity, and moderate to good yields. This methodology offers an appealing approach to obtaining keto-containing polycyclic quinazolinones with pharmaceutical value. [Display omitted] A method for synthesizing polycyclic quinazolinone derivatives with ketoalkyl substitutions has been developed through strong acid-catalyzed radical tandem alkylation/cyclization of unactivated alkenes with readily available ketones under microwave irradiation. The mechanistic studies revealed that the strong acid-catalyzed tandem alkylation/cyclization occurs through a radical pathway. This approach provides a potential route for the functionalization of quinazolinones that may find wide applications in pharmaceutical preparation. [ABSTRACT FROM AUTHOR]

[Display omitted] • A library of triazole–quinazolinone molecular hybrids have been synthesized using click reaction. • Six derivatives emerged as potent agents against plasmodium species P. falciparum. • Three derivatives have displayed potent antitubercular activity against M. tuberculosis (MTB) H37Rv strain. In a quest to discover new antimalarial and antitubercular drugs, we have designed and synthesized a series of novel triazole–quinazolinone hybrids. The in vitro screening of the triazole–quinazolinone hybrid entities against the plasmodium species P. falciparum offered potent antimalarial molecules 6c , 6d , 6f , 6g , 6j & 6k owing comparable activity to the reference drugs. Furthermore, the target compounds were evaluated in vitro against Mycobacterium tuberculosis (MTB) H37Rv strain. Among the screened compounds, 6c , 6d and 6l were found to be the most active molecules with a MIC values of 19.57–40.68 μM. The cytotoxicity of the most active compounds was studied against RAW 264.7 cell line by MTT assay and no toxicity was observed. The computational study including drug likeness and ADMET profiling, DFT, and molecular docking study was done to explore the features of target molecules. The compounds 6a , 6g , and 6k exhibited highest binding affinity of −10.3 kcal/mol with docked molecular targets from M. tuberculosis. Molecular docking study indicates that all the molecules are binding to the falcipain 2 protease (PDB: 6SSZ) of the P. falciparum. Our findings indicated that these new triazole–quinazolinone hybrids may be considered hit molecules for further optimization studies. [ABSTRACT FROM AUTHOR]

The discovery of effective multitarget-directed ligands (MTDLs) against multifactorial Alzheimer's disease (AD) remnants has been focused in an incessant drug discovery pursuit. In this perception, the current study explores the rational design, synthesis, and evaluation of 26 quinazolinone-hydrazine cyanoacetamide hybrids 7(a-j) , 8(a-j) , and 9(a-f) as MTDLs against AD. These new compounds were synthesized in four-step processes using simple phthalimide as the starting material without any major workup procedures and were characterized by different spectroscopic techniques. In Ellman's assay, the most potent analogues 7i , 8j , and 9d were identified as selective and mixed-type inhibitors of hAChE. Furthermore, biophysical and computational assessments revealed that the analogues 7i , 8j , and 9d were bound to both the catalytic active site and peripheral anionic site of hAChE with high affinity. The molecular dynamics simulation analysis highlighted the conformational changes of hAChE upon binding of 7i , 8j , and 9d and also the stability of resulting biomolecular systems all over 100 ns simulations. In addition to antioxidant activity, the most active congeners were found to protect substantially SK-N-SH cells from oxidative damage. Decisively, the most active analogues 7i , 8j , and 9d were assessed as potent Aβ 1-42 fibril modulators and protective agents against Aβ 1-42 -induced toxicity in SH-SY5Y cells. Additionally, glioblastoma C6 cell-based assays also demonstrated the use of the most active congeners 7i , 8j , and 9d as protective agents against Aβ 1-42 -induced toxicity. Overall, this multifunctional capacity of quinazolinone-hydrazine cyanoacetamide hybrids demonstrated the noteworthy potential of these hybrids to develop as effectual MTDLs against AD. However, further pharmacokinetics, toxicology, and behavioral studies are warranted.

Quinazoline and quinazolinone derivatives piqued medicinal chemistry interest in developing novel drug candidates owing to their pharmacological potential. They are important chemicals for the synthesis of a variety of physiologically significant and pharmacologically useful molecules. Quinazoline and quinazolinone derivatives have anticancer, anti-inflammatory, antidiabetic, anticonvulsant, antiviral, and antimicrobial potential. The increased understanding of quinazoline and quinazolinone derivatives in biological activities provides opportunities for new medicinal products. The present review focuses on novel advances in the synthesis of these important scaffolds and other medicinal aspects involving drug design, structure-activity relationship, and action mechanisms of quinazoline and quinazolinone derivatives to help in the development of new quinazoline and quinazolinone derivatives., (© 2024 Deutsche Pharmazeutische Gesellschaft.)

• We developed a novel series of pyrido[2,1-b]quinazoline-6-carboxamide compounds (8a-t) designed specifically as RNA polymerase inhibitors. • Immunofluorescence analysis using the RPA 194 antibody revealed a significant decrease in RPA 194 expression. • Assessment of apoptosis-inducing activity confirmed that treatment with 8e led to apoptosis in up to 43 % of HepG2 cells. • Molecular docking studies further validated the effective interaction of derivatives 8e and 8l with a hexamer of the DNA double helix, showcasing favorable binding energies and modes. In the present study, a new series of quinazolin-4(3 H)-one based compounds was designed, synthesized, and biologically evaluated as potential anticancer. The 11-oxo-11 H -pyrido [2, 1-b] quinazoline-6-carboxylic acid 3a-c was synthesized as a precursor to prepare the pyridoquinazolinecarboxamides derivatives with different amines (7a-e). The molecular structures of these novel compounds were characterized through the analysis of various spectroscopic methods. Following that, the antiproliferative activity of synthesized compounds was evaluated against HepG2, MCF7, and HT-29 cancer cell lines. Compound 8e , with an IC50 of 2.07 µM, demonstrated higher potency than doxorubicin (IC 50 =2.15±0.021 µM) against HepG2 cancer cells, while the potency of 8l against HepG2 (liver cancer) was comparable to Dox. The effect of 8e and 8l on the destruction of Pol I subunit of RPA194 was evaluated; 8e and 8l exhibited a reduction in RPA 194 compared to the control. The 8e induces 43.1 % and 8l 37.6 % of HepG2 cell deaths, with doxorubicin being 52 %. Molecular modeling studies show the good binding free energies ranged from -8.32 to -11.7 kcal/mol with a hexamer of the DNA double helix. Accordingly, our findings imply that these derivatives serve as promising precursors for the design of potent anticancer agents. [ABSTRACT FROM AUTHOR]

• 26 novel and skeletally diverse quinazolinones were synthesized. • Five of the novel compounds significantly reduced the cell viability in CAL 27 cells when compared to the NOE cells. • In the LDH-coupled enzyme assay, 17n, 17x , and 17z showed their ability to activate pyruvate kinase M2 (PKM2). • Fluorescent microscopy revealed an increased apoptotic impact on CAL 27 cells. • The anti-oral cancer activity operates via a caspase 3-dependent mechanism. This study aims at fostering and uplifting the profile of tumor pyruvate kinase M2 (PKM2) modulators via development of novel, effective and selective agents against oral cancer cells. Towards this end, we designed and synthesized a novel and skeletally diverse library of quinazolinones. Notably, five of the newly synthesised compounds significantly reduced the cell viability of oral cancer cells (CAL 27) when compared to the normal oral epithelial (NOE) cells. In the lactate dehydrogenase (LDH)-coupled enzyme assay, the derivatives (17n, 17x and 17z) showed a potent PKM2 activation profile with IC 50 values ranging from 14 μM to 26 μM. Of note, these three PKM2 activators displayed enhanced apoptotic effect on CAL 27 cells as analysed by the increased chromatin condensation, nuclear fragmentation and apoptotic bodies observed with Hoechst 33342 and annexin V-PI staining following fluorescent microscopy. This was corroborated by the enhancements in the mRNA expression of caspase 3 which is the final death-executioner. Additionally, flow cytometry analysis revealed that compound 17n killed CAL 27 cancer cells by cell cycle arrest in the G2/M phase. The computational studies revealed that these molecules preferentially interact with PKM2 at dimeric interface site similar to the reported PKM2 modulators and exhibit similar binding pattern. Overall, our results provide conclusive evidence that the quinazolinones possess strong anti-proliferative effects on CAL 27 cells with minimal toxicity towards NOE cells at similar concentrations and induced apoptotic machinery via caspase-3 dependent pathway. Hence, these PKM2 activators may serve as potential hits for further development as anti-cancer agents. [Display omitted] [ABSTRACT FROM AUTHOR]

Hypochlorite plays an important role in life system, so it is necessary to develop an effective method to detect hypochlorite. In view of the advantages of fluorescent probes at present, we constructed two novel fluorescent probes (PTQ , PTN) based on phenothiazine, which can be used for specific detection of ClO−. Due to the introduction of nitrogen-containing heterocyclic quinazolinone, PTQ shows better optical properties: a great stokes shift (190 nm), excellent selectivity and anti-interference, low detection limit (0.054 μM) and fast response time (20 s). The color change of ClO− identified by the probe PTQ can be observed with naked eyes under sunlight. Through the calculation of density functional theory and mass spectrometry experiments, the mechanism of fluorescence detection of ClO− by PTQ was further verified. Furthermore, PTQ also realized the detection of ClO− in actual water samples and test strips, and achieved remarkable results. Due to its better optical properties and low cytotoxicity, probe PTQ has been successfully applied to the fluorescence detection of ClO− in living cells. [Display omitted] • The probe PTQ and PTN are sensitive (LOD = 0.054 μM, 0.122 μM), great stokes shift (190 nm, 132 nm) and fast for ClO−. • The probe PTQ has been successfully used for imaging detection of exogenous ClO− in VSMC cells with low toxicity. • The test strips of the probe PTQ can be used for recognition of ClO− by fluorescence. • The probe PTQ has been recognized ClO− with naked eyes. • The probe PTQ realized the detection of ClO− in actual water samples. [ABSTRACT FROM AUTHOR]

• Design of hybrid analogues with indolyl oxoacetamide & quinazolinone scaffold synthesis and in vitro PL inhibitory screening of the synthesized analogues. • Enzyme kinetics study of the most potent analogue to check the type of inhibition. • Cytotoxic effect of the most potent analogue using the MTT assay. Pancreatic lipase (PL) is a key enzyme responsible for the digestion of dietary fat. Hence the inhibition of PL is an effective strategy for mitigating obesity. In this study, a novel series of 18 indolyl oxoacetamide–quinazolinone hybrid analogues (9a-h, 13aa-13fd) were designed, synthesized, and evaluated for PL inhibition activity. An approach of molecular hybridization was utilized by considering the PL inhibitory potential of indole, α-ketoamide, and quinazolinone scaffolds. A Propyl linker was attached for better binding at the PL active site, leading to enhanced PL inhibitory potential. Among all the synthesized analogues, 13be exhibited the highest PL inhibitory activity (IC 50 = 4.71 ± 0.851 μM) with a docking score of -147.06 kcal/mol. The activities of all the synthesized analogues were compared with the orlistat (IC 50 = 0.86 ± 0.090 µM). The most potent analogue, 13be revealed the competitive mode of enzyme inhibition with the K i value of 1.826 µM. The molecular docking and dynamics simulation analysis also revealed the strong binding of 13be at the active site of PL. Interestingly, the potent analogue 13be when tested on RAW 264.7 cell line using MTT assay, was found to be nontoxic at a concentration range of 1-20 µM. Therefore, the current work validates the effectiveness of the molecular hybridization approach for designing indolyl oxoacetamide–quinazolinone hybrids for inhibiting PL. [Display omitted] [ABSTRACT FROM AUTHOR]

[Display omitted] A metal-free approach to the construction of novel spiro[ quinazoline - thiophen ]one framework via an acetic acid promoted formal [3 + 2] cycloaddition is developed. A library of functionalized spiro[quinazoline-thiophen](thi)ones were efficiently synthesized in good to excellent yields under mild conditions. The protocol features high atom-economy, an eco-benign catalyst and molecular diversity. [ABSTRACT FROM AUTHOR]

Dysregulation of the Wnt signaling pathway contributes to the development of many cancer types. Natural compounds produced with biotechnological systems have been the focus of research for being a new drug candidate both with unlimited resources and cost-effective production. In this study, it was aimed to reveal the effects of isopropylchaetominine on cytotoxic, cytostatic, apoptotic and Wnt signaling pathways in brain, pancreatic and prostate cancer. The IC 50 values of isopropylchaetominine in U-87 MG, PANC1, PC3 and LNCaP cells were calculated as 91.94 μM, 41.68 μM, 54.54 μM and 7.86 μM in 72nd h, respectively. The metabolite arrests the cell cycle in G 0 /G 1 phase in each cancer cells. Iso-propylchaetominine induced a 4.3-fold and 1.9-fold increase in apoptosis in PC3 and PANC1 cells, respectively. The toxicity of isopropylchaetominine in healthy fibroblast cells was assessed using the annexin V method, and no significant apoptotic activity was observed between the groups treated with the active substance and untreated. In U-87 MG, PANC1, PC3, and LNCaP cells under treatment with isopropylchaetominin, the expression levels of DKK3, TLE1, AES, DKK1, FRZB, DAB2, AXIN1/2, PPARD, SFRP4, APC and SOX1 7 tumor suppressor genes increased significantly. Decreases in expression of Wnt1, Wnt2, Wnt3, Wnt4, Wnt5, Wnt6, Wnt10, Wnt11, FRZ2, FRZ3, FRZ7, TCF7L1, BCL9, PYGO, CCND2, c-MYC, WISP1 and CTNNB1 oncogenic genes were detected. All these result shows that isopropylchaetominine can present promising new treatment strategy in different cancer types. [Display omitted] • Iso-propylchaetominine exhibits anticancer activity in in vitro models of brain, pancreatic and prostate cancer. • Iso-propylchaetominin arrests the cell cycle in the G0/G1 phase. • Iso-propylchaetominine regulates the Wnt signaling pathway. • Iso-propylchaetominine causes cell cycle arrest by regulating the Wnt pathway. [ABSTRACT FROM AUTHOR]

[Display omitted] • Quinazolinone derivatives were designed keeping Ispinesib and Idelalisib as reference structures. • Compounds 3a, 3b, 3e, 3g and 3h revealed nanomolar potency against KSP and PI3Kδ. • Compounds were found to be active against MDA-MB-231 breast cancer cells. • Anticancer activity was found to be associated with their P53 -dependent apoptotic activity. Triple-negative breast cancer (TNBC) comprises 10 % to 20 % of breast cancer, however, it is more dangerous than other types of breast cancer, because it lacks druggable targets, such as the estrogen receptors (ER) and the progesterone receptor (PR), and has under expressed receptor tyrosine kinase, ErbB2. Present targeted therapies are not very effective and other choices include invasive procedures like surgery or less invasive ones like radiotherapy and chemotherapy. This study investigated the potential anticancer activity of some novel quinazolinone derivatives that were designed on the structural framework of two approved anticancer drugs, Ispinesib (KSP inhibitor) and Idelalisib (PI3Kδ inhibitor), to find out solutions for TNBC. All the designed derivatives (3a-l) were subjected to extra precision molecular docking and were synthesized and spectrally characterized. In vitro enzyme inhibition assay of compounds (3a, 3b, 3e, 3 g and 3 h) revealed their nanomolar inhibitory potential against the anticancer targets, KSP and PI3Kδ. Using MTT assay, the cytotoxic potential of compounds 3a, 3b and 3e were found highest against MDA-MB-231 cells with an IC 50 of 14.51 µM, 16.27 µM, and 9.97 µM, respectively. Remarkably, these compounds were recorded safe against the oral epithelial normal cells with an IC 50 values of 293.60 µM, 261.43 µM, and 222 µM, respectively. The anticancer potential of these compounds against MDA-MB-231 cells was revealed to be associated with their apoptotic activity. This was established by examination with the inverted microscope that revealed the appearance of various apoptotic features like cell shrinkage, apoptotic bodies, and membrane blebbing. Using flow cytometry, the Annexin V/PI-stained cancer cells showed an increase in early and late apoptotic cells. In addition, DNA fragmentation was revealed to occur after treatment with the tested compounds by gel electrophoresis. The relative gene expression of pro-apoptotic and anti-apoptotic genes revealed an overexpression of the P53 and BAX genes and a downregulation of the BCL-2 gene by real-time PCR. So, this work proved that compounds 3a, 3b, and 3e could be developed as anticancer candidates, via their P53-dependent apoptotic activity. [ABSTRACT FROM AUTHOR]

[Display omitted] • A series of quinazolinone derivatives were synthesized and tested preliminarily for their in vitro AChE inhibitory activity. • Compounds 4b, 5a, 6f, 6 h, 7b were tested for their enhancing activity of cognitive function by Morris water maze test. • Compounds 4b, 5a, 6f, 6 h, 7b were tested for their in vivo brain and serum AChE inhibitory activities. • Selected compounds 4b, 5a, 6f, 6 h, 7b were tested for their in vivo anti inflammatory activity (anti TNF-α, NF-ĸB, IL-1β and IL-6 activity). • Selected compounds 4b, 5a, 6f, 6 h, 7b were tested for their in vivo anti-oxidant activity. • Histopathological examination was carried out to better explain the cortical and hippocampal changes in cerebral tissues. • Compounds 6f, 6h, 7b showed promising AChE enzyme inhibitory activity and anti-inflammatory activity. • Docking study illustrates the binding modes in AchE enzyme along with the reference compound (donepezil). Since Alzheimer disease is one of the most prevalent types of dementia with a high mortality and disability rate, so development of multi-target drugs becomes the major strategy for battling AD. This study shows the development of a series of quinazolinone based derivatives as novel, multifunctional anti-AD drugs that exhibit both cholinesterase inhibitory and anti-inflammatory properties. The preliminary results of the in vitro AChE inhibition activity showed that compounds 4b, 5a, 6f, 6 h and 7b were better represented for further evaluation. Furthermore, in-vivo AChE inhibition activity and behavior Morris water maze test against donepezil as reference drug were evaluated. Additionally, hippocampal inflammatory markers; TNF-α, NFĸB, IL-1β and IL-6 and antioxidant markers; SOD and MDA were assessed to evaluate the efficacy of quinazolinone derivatives against AD hallmarks. The results showed that 6f , 6 h and 7b have promising anti-acetylcholinesterase, anti-inflammatory and antioxidant activities thus, have a significant effect in treatment of AD. Moreover, Histopathological examination revealed that 6f, 6 h and 7b derivatives have neuroprotective effect against neuronal damage caused by induced scopolamine model in mice. Finally, the binding ability of the synthesized derivatives to the target, AChE was investigated through molecular docking which reflected significant interactions to the target based on their docking binding scores. Hence, the newly designed quinazolinone derivatives possess promising anti-acetylcholinesterase activity and challenging for the management of AD in the future. [ABSTRACT FROM AUTHOR]

Cancer is a broad classification of diseases that can affect any organ or body tissue due to aberrant cellular proliferation for unknown reasons. Many present chemotherapeutic drugs are highly toxic and have little selectivity. Additionally, they lead to the development of medication resistance. Therefore, developing tailored chemotherapeutic drugs with minimal side effects and good selectivity is crucial for cancer treatment. 2-(1 H )-Quinazolinone is one of the vital scaffold and anticancer activity is one of the prominent biological activities of this class. Here we report the novel set of amide-enriched 2-(1 H )-quinazolinone derivatives ( 7a-j ) and their apoptotic activity with the help of MTT assay method against four human cancer cell lines: PC3 (prostate cancer), DU-145 (prostate cancer), A549 (lung cancer), and MCF7 (breast cancer). When compared to etoposide, every synthetic test compound ( 7a-j ) exhibited moderate to excellent activity. The IC 50 values of the new amide derivatives ( 7a-j ) varied from 0.07 ± 0.0061 μM to 10.8 ± 0.69 μM. While the positive control, etoposide, exhibited 1.97 ± 0.45 μM to 3.08 ± 0.135 μM range. Among the novel amide derivatives ( 7a-j ), in particular, 7i and 7j showed strong apoptotic activity against MCF7; 7h showed against PC3, and 7g showed against DU-145. Molecular docking studies of test compounds ( 7a-j ) with the EGFR tyrosine kinase domain (PDB ID: 1M17) protein provided the significant docking scores for each test compound ( 7a-j ) (-9.00 to -9.67 kcal/mol). Additionally, DFT investigations and MD simulations validated the predictions of molecular docking. According to the findings of the ADME analysis, oral absorption by humans is anticipated to be higher than 85 % for all test compounds., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Author(s).)

To develop aryloxyphenoxypropionate herbicides with a novel structure and improved activity, a total of 39 aryloxyphenoxypropionate/amide derivatives containing quinazolinone moiety were synthesized and further bioevaluated. The bioassay results in the greenhouse showed that most of the target compounds had good herbicidal activity under postemergence conditions, of which, QPP-I-6 displayed excellent herbicidal activity against Echinochloa crusgalli , Digitaria sanguinalis , Spartina alterniflora , Eleusine indica, and Pennisetum alopecuroides with inhibition rates >90% at a dosage of 187.5 g ha -1 . More importantly, QPP-I-6 displayed higher crop safety to Gossypium hirsutum , Glycine max , and Arachis hypogaea than the commercial herbicide quizalofop- p -ethyl. Studying the molecular mode of action by phenotypic observation, membrane permeability evaluation, transcriptomic analysis, and in vivo ACCase activity evaluation reveals that QPP-I-6 is a novel ACCase inhibitor. The present work demonstrates that QPP-I-6 can serve as a lead compound for further developing novel ACCase-inhibiting herbicides.

The promising quinazolinone-based pyridine derivatives (4a-j) were synthesized and subsequently tested for their antimycobacterial activities against the various drug-sensitive and drug-resistant Mycobacterium tuberculosis (Mtb) strains to combat infectious diseases and address growing concerns about the devastating effects of tuberculosis (TB). Utilizing 1 H NMR, 13 C NMR, and mass spectra, the structural and molecular confirmation of the synthesized compounds were deciphered. With minimum inhibitory concentration (MIC) values ranging from 0.31 to 19.13 μM, the results showed that compounds 4e and 4f showed promise anti-TB action against both drug-sensitive and drug-resistant TB strains. To study the cytotoxicity of synthesized molecules, normal Vero and mouse macrophage (RAW264.7) cell lines were utilized. Remarkably, it was revealed that at the highest concentration tested, none of the newly synthesized molecules were toxic to the Vero cell line. The binding patterns of the potent compounds 4b, 4e and 4f in the active site of the mycobacterial membrane protein Large 3 (MmpL3) protein are also revealed by molecular docking studies, which has contributed to the development of a structural rationale for Mtb inhibition. The physicochemical characteristics of the compounds were then predicted using theoretical calculations. Overall, the molecular docking results, physiochemical properties, and observed antimycobacterial activity all point to compound 4e with trifluoromethyl and compound 4f with nitro moiety as potential quinazolinone linked pyridine-based MmpL3 inhibitors.Communicated by Ramaswamy H. Sarma.

The production of penicillin-binding protein 2a (PBP2a), a cell wall synthesis protein, is primarily responsible for the high-level resistance observed in methicillin-resistant Staphylococcus aureus (MRSA). PBP2a exhibits a significantly reduced affinity for most β-lactam antibiotics owing to its tightly closed active site. Quinazolinones (QNE), a novel class of non-β-lactam antibiotics, could initiate the allosteric regulation of PBP2a, resulting in the opening of the initially closed active pocket. Based on our previous study, we have a basic understanding of the dual-site inhibitor ceftaroline (CFT) induced allosteric regulation of PBP2a. However, there are still limitations in the knowledge of how combining medicines, QNE and piperacillin (PIP), induce the allosteric response of PBP2a and inhibit its function. Herein, molecular dynamics (MD) simulations were performed to elucidate the intricate mechanisms underlying the combination mode of QNE and PIP. Our study successfully captured the opening process of the active pocket upon the binding of the QNE at the allosteric site, which alters the signaling pathways with a favorable transmission to the active site. Subsequent docking experiments with different conformational states of the active pocket indicated that all three inhibitors, PIP, QNE, and CFT, exhibited higher docking scores and more favorable docking poses to the open active pocket. These findings reveal the implied mechanism of QNE-mediated allostery underlying combination therapy and provide novel insights into developing innovative therapeutic modalities against MRSA.Communicated by Ramaswamy H. Sarma.